News | May 27, 2026
Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Subscribe To Our Newsletter & Stay Updated
